Spots Global Cancer Trial Database for CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC

Official Title: Computed Tomography-based Radiomics of Axillary Lymph Node Pathological Complete Remission (ypN0) in Breast Cancer Undergoing Neoadjuvant Chemotherapy

Study ID: NCT04457700

Conditions

Triple-negative Breast Cancer

HER2-positive Breast Cancer

Interventions

Study Description

Brief Summary: This is a prospective, single-center, non-randomized, non-controlled observational study.

Detailed Description: Almost 55-62% of patients with triple-negative or human epidermal growth factor receptor 2 (HER2) positive, node-positive breast cancer achieve an axillary pathologic complete remission (pCR) after neoadjuvant chemotherapy (NAC). To avoid surgery post-NAC, it is paramount to accurately identify patients who achieve pCR in axillary lymph node (ALN). We found that patients with normal-appearing lymph nodes on computed tomography (CT) based radiomics of the axilla after chemotherapy had a lower risk of developing residual nodal disease. However, the features of CT-based radiomics for pCR ALN following NAC has not been established yet. This study aimed to assess the performance of CT-based radiomics in evaluating the response and predicting pCR of metastatic lymph nodes after NAC in breast cancer patients.